Diabetic neuropathy: new strategies for treatment
- 26 June 2007
- journal article
- review article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 10 (2), 99-108
- https://doi.org/10.1111/j.1463-1326.2007.00741.x
Abstract
Current therapeutic possibilities can be divided into two groups: the pathogenetically oriented and the symptomatic therapy. One of the most important component of etiology-based treatment is the stabilization of glycemic control. Based on efficacy and safety data benfotiamine and alpha-lipoic acid should be considered as first choices among pathogenetically oriented treatments of diabetic neuropathy. Promising data were published about the aldose reductase inhibitor ranirestat. The symptomatic effect of antiepileptic drugs in diabetic painful neuropathy (DPN) is originated from several possible pharmacological properties. Pregabalin and gabapentin have the highest efficacy and the lowest frequency of adverse events among these drugs. Antidepressants also extensively used for symptomatic treatment in DPN. In the last years several studies were published about the benefial effect of duloxetine. Most likely combination therapy will be frequently applied in the future for the treatment of DPN, the optimal choice could be to combine pathogenetically oriented and symptomatic treatment.Keywords
This publication has 80 references indexed in Scilit:
- Lifestyle Intervention for Pre-Diabetic NeuropathyDiabetes Care, 2006
- Neuropathy Among the Diabetes Control and Complications Trial Cohort 8 Years After Trial CompletionDiabetes Care, 2006
- Long-Term Effects of Ranirestat (AS-3201) on Peripheral Nerve Function in Patients With Diabetic Sensorimotor PolyneuropathyDiabetes Care, 2006
- Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C β-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trialClinical Therapeutics, 2005
- Vascular Risk Factors and Diabetic NeuropathyNew England Journal of Medicine, 2005
- Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled studyPain, 2004
- Multifactorial Intervention and Cardiovascular Disease in Patients with Type 2 DiabetesNew England Journal of Medicine, 2003
- Autonomic neuropathy is associated with increased cardiovascular risk factors: the EURODIAB IDDM Complications StudyDiabetic Medicine, 2002
- Effects of the protein kinase Cβ inhibitor LY333531 on neural and vascular function in rats with streptozotocin-induced diabetesClinical Science, 2002
- Effects of alpha-lipoic acid on microcirculation in patients with peripheral diabetic neuropathyExperimental and Clinical Endocrinology & Diabetes, 2000